Year-end Report January-December 2010

Period October-December

· The Group's net sales for the period were SEK 142 (153) million. After
adjustment for the disposal of the OTC products, organic growth was 9%.

· EBITDA for the period amounted to SEK 21* (23) million. After adjustment for
the disposal of the OTC products and closing-down costs in Poland, EBITDA
amounted to SEK 24 (14) million.

· Operating profit was SEK 7** (13) million.

· Profit after tax for the period was SEK 0*** (2) million.

· Earnings per share after tax, before and after dilution, for the period was
SEK 0.00 (0.01).

Period January-December

· The Group's net sales for the period were SEK 553 (634) million.

· EBITDA for the period amounted to SEK -16* (98) million.

· Operating profit/loss was SEK -122** (71) million.

· Profit/loss after tax for the period was SEK -163*** (18) million.

· Earnings per share after tax, before and after dilution, for the period was
SEK -0.48 (0.05).

Significant events during the period January-December

· The Board decided to streamline operations and focus on prescription
pharmaceuticals in the Nordic region. These measures resulted in a strong fourth
quarter for BioPhausia.

· BioPhausia sold OTC products to Meda AB for SEK 190 million, resulting in a
capital loss of SEK 74 million.

· Bank loan repayments amounted to SEK 245 million during the period.

· BioPhausia became the main supplier of parallel-imported pharmaceuticals to
Apoteksgruppen.

· Impairment losses of SEK 82 million were recognised for intangible assets and
SEK 18 million for inventories.

· Niklas Prager was elected as the new Chairman of the Board of BioPhausia.

· Maris Hartmanis took up the position of BioPhausia CEO on 9 August.




[HUG#1490107]